Clinical Data Novo says oral semaglutide works in diabetic kids PharmaphorumNovo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year.Clinical DataMetabolic & GLP-1Read full story pharminent April 23, 2026 (Last updated: April 23, 2026) Pharmaphorum Novo Nordisk will file oral formulations of its GLP-1 agonist semaglutide for children and adolescents with type 2 diabetes later this year. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO changeNext: BBOT shakes up leadership as RAS competitors get more visibility Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026